# Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

> **NCT07047014** · PHASE3 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 596 (estimated)

## Conditions studied

- Stroke, Ischemic
- Medium Vessel Occlusions

## Interventions

- **DRUG:** Tenecteplase (0.25mg/kg)
- **DRUG:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07047014
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 596 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- First Affiliated Hospital of Zhejiang University
- Chinese Stroke Association

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07047014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07047014, "Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07047014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*